PMID- 36152477
OWN - NLM
STAT- MEDLINE
DCOM- 20221024
LR  - 20221109
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 173
DP  - 2022 Nov
TI  - Safety of image guided research biopsies in patients with thoracic malignancies.
PG  - 53-57
LID - S0169-5002(22)00614-6 [pii]
LID - 10.1016/j.lungcan.2022.08.024 [doi]
AB  - OBJECTIVE: A common opportunity to collect research samples is during 
      image-guided percutaneous core needle biopsies (CNBs) performed when clinically 
      indicated or for assessing clinical trial eligibility. The relative safety of 
      extra CNBs collected for research is undefined. MATERIALS AND METHODS: Patients 
      who underwent CNB for research purposes only [RO], as clinically indicated [CI], 
      or as part of a clinical trial [CT] were identified. 30-day post-procedure 
      adverse events (AEs) among the cohorts were examined and compared to the 2020 
      Society of Interventional Radiology QI guidelines. RESULTS: 236 patients with 
      thoracic cancers (90 % NSCLC, 5 % SCLC, 4 % mesothelioma, and 1 % thymic) had 292 
      CNBs (63 RO, 229 CI + CT). AEs occurred in 13 % of both the RO and CI + CT 
      groups. Compared to the CI + CT group, the RO group did not have a higher 
      pneumothorax incidence (RO: 5/29 [17 %], CI + CT: 18/114 [16 %], p = 0.79); both 
      were below the suggested QI threshold of 45 % for pneumothorax. There was a 
      negative association between number of cores obtained and risk of AE (AE vs no AE 
      mean cores = 3.5 vs 4.8). After adjusting for the number of cores and smoking 
      history, RO vs CI + CT lung biopsies had a higher risk of AEs (adjusted relative 
      risk [aRR] = 2.44, 1.08-5.55, p = 0.03 vs non-lung aRR = 0.86, 0.10-7.09, 
      p = 0.89). CONCLUSION: CNBs performed for research purposes do not have a 
      significantly increased risk of AEs when compared to those performed for clinical 
      trials and/or when clinically indicated. However, AEs were most frequent in lung 
      biopsies. When performing research biopsies, a target other than lung may be 
      preferred when clinically appropriate.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Soosman, Steffan K
AU  - Soosman SK
AD  - Division of Angiography and Interventional Radiology, Department of Radiology, 
      Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
FAU - Schenker, Matthew P
AU  - Schenker MP
AD  - Division of Angiography and Interventional Radiology, Department of Radiology, 
      Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
FAU - Mazzola, Emanuele
AU  - Mazzola E
AD  - Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber 
      Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical 
      School, Boston, MA, USA.
FAU - Voligny, Emma
AU  - Voligny E
AD  - Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber 
      Cancer Institute, Boston, MA, USA.
FAU - Smokovich, Anna
AU  - Smokovich A
AD  - Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber 
      Cancer Institute, Boston, MA, USA.
FAU - Bay, Camden
AU  - Bay C
AD  - Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, 
      Boston, MA, USA.
FAU - Nguyen, Tom
AU  - Nguyen T
AD  - Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber 
      Cancer Institute, Boston, MA, USA.
FAU - Michael, Kesi
AU  - Michael K
AD  - Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber 
      Cancer Institute, Boston, MA, USA.
FAU - Janne, Pasi A
AU  - Janne PA
AD  - Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber 
      Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical 
      School, Boston, MA, USA.
FAU - Rabin, Michael
AU  - Rabin M
AD  - Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber 
      Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical 
      School, Boston, MA, USA.
FAU - Glazer, Daniel I
AU  - Glazer DI
AD  - Division of Abdominal Imaging and Intervention, Department of Radiology, Brigham 
      and Women's Hospital, Harvard Medical School, Boston, MA, USA.
FAU - Johnson, Bruce E
AU  - Johnson BE
AD  - Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber 
      Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical 
      School, Boston, MA, USA.
FAU - Luo, Jia
AU  - Luo J
AD  - Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber 
      Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical 
      School, Boston, MA, USA. Electronic address: jia_luo@dfci.harvard.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220917
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
SB  - IM
MH  - Humans
MH  - Image-Guided Biopsy/adverse effects/methods
MH  - *Lung Neoplasms/pathology
MH  - *Pneumothorax/epidemiology/etiology
MH  - *Thoracic Neoplasms
MH  - Tomography, X-Ray Computed
MH  - Clinical Trials as Topic
OTO - NOTNLM
OT  - Lung
OT  - Lung cancer
OT  - Research biopsy
OT  - Safety
OT  - Thoracic malignancies
COIS- Declaration of Competing Interest The authors declare the following financial 
      interests/personal relationships which may be considered as potential competing 
      interests: C.B. reports personal fees from Takeda. P.A.J. reports grants from The 
      Mark Foundation for Cancer Research, grants from American Cancer Society, during 
      the conduct of the study; grants and personal fees from AstraZeneca, grants and 
      personal fees from Boehringer Ingelheim, personal fees from Pfizer, personal fees 
      from Roche/Genentech, personal fees from Chugai Pharmaceuticals, personal fees 
      from Ignyta, personal fees from LOXO Oncology, grants and personal fees from Eli 
      Lilly, personal fees from SFJ Pharmaceuticals, personal fees from Voronoi, grants 
      and personal fees from Daiichi Sankyo, personal fees from Biocartis, personal 
      fees from Novartis, personal fees from Sanofi, grants and personal fees from 
      Takeda Oncology, personal fees from Transcenta, personal fees from Silicon 
      Therapeutics, personal fees from Syndax, personal fees from Nuvalent, personal 
      fees from Bayer, personal fees from Esai, grants from PUMA, grants from Astellas 
      Pharmaceuticals, grants from Revolution Medicines, personal fees from Mirati 
      Therapeutics, outside the submitted work. J.L has received honoraria from 
      Targeted Oncology and Physicians' Education Resource; and personal fees from 
      Erasca, Blueprint Medicines, and Daiichi Sankyo. B.E.J reports personal fees from 
      Novartis, Boston Pharmaceuticals, Checkpoint Therapeutics, Chugai, Daiichi 
      Sankyo, AstraZeneca, Foundation Medicine, G1 Therapeutics, Genentech, 
      GlaxoSmithKline, Hengrui Therapeutics, Janssen, Jazz Pharmaceuticals, and Eli 
      Lilly outside the submitted work; in addition, B.E. Johnson has a patent for EGFR 
      Mutation Testing licensed and with royalties paid from DFCI and MGH.
EDAT- 2022/09/25 06:00
MHDA- 2022/10/21 06:00
CRDT- 2022/09/24 18:23
PHST- 2022/06/16 00:00 [received]
PHST- 2022/08/09 00:00 [revised]
PHST- 2022/08/31 00:00 [accepted]
PHST- 2022/09/25 06:00 [pubmed]
PHST- 2022/10/21 06:00 [medline]
PHST- 2022/09/24 18:23 [entrez]
AID - S0169-5002(22)00614-6 [pii]
AID - 10.1016/j.lungcan.2022.08.024 [doi]
PST - ppublish
SO  - Lung Cancer. 2022 Nov;173:53-57. doi: 10.1016/j.lungcan.2022.08.024. Epub 2022 
      Sep 17.